Yes ...some good indicative information. If you have a look at...

Yes ...some good indicative information.
If you have a look at the annual accounts gross margin on sales of $1.33m was 62%.

So based on the information above US$64,000 per unit = A$82,000 . Maybe a range of A$80,000 to A$100,000 to Zeiss which would equate to 12-16 pre production units having sold during the year.

In the most recent presentation Optiscan estimates that the “Digital Biopsy” neurosurgery market potential between 4,000 and 8,000 systems globally.

As an example some indicative numbers using the above.

If in year one (after all approvals) penetration of 1% p.a is achieved - say mid point =60 units this equates to revenue of $5m-$6m with gross margin of $3m-$3.75m . About break even point for the total business.

If penetration of 2% p.a is achieved - say mid point 120 units this equates to revenue of $10m-$12m with gross margin of $6m-$7.5m - NPBT of around $3m-$4m perhaps.

Note and the above does not include any sales of ViewnVino or other OIL sale initiatives outside of the Zeiss collaboration!

As the Chairman said in his most recent note.

Whilst asking that you please consider the disclaimer below and our Appendix 4E, we anticipate the following:
• With our Carl Zeiss Meditec (CZM) collaboration, we anticipate revenues in excess of $2m over the remainder of this financial year as a minimum – with an upside we believe will be well in excess of that depending on the effectiveness of the upcoming 2017 product launch by CZM (more details to follow on this via a separate announcement shortly)
• For ViewnVivo, our expectations from our distribution partners in the USA and China are for the delivery of $2m in revenue in the next 12 months – again with an upside we believe will be well in excess of that amount. • Additionally, we expect to receive just under $1m via an R&D rebate in late 2017.
Overall, with significant anticipated demand for our products through our global partner Carl Zeiss Meditec (CZM) and our ViewnVivo systems, Optiscan is on the verge of delivering a significantly improved performance for the 2017/18 period and beyond. Indeed, our goal of a profitable 2017/18 is well and truly on track.

And from last years Chairs AGM address:

The last 20 years have been ones of constant promise – 2017 will be a year of delivery.

So strap yourself in - it is going to be quite a ride.